Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes

医学 血糖性 安慰剂 双盲 内科学 双盲研究 胃肠病学 胰岛素 病理 替代医学
作者
Franklin J. Zieve,Marcia F. Kalin,Sherwyn Schwartz,Michael R. Jones,William L. Bailey
出处
期刊:Clinical Therapeutics [Elsevier BV]
卷期号:29 (1): 74-83 被引量:219
标识
DOI:10.1016/j.clinthera.2007.01.003
摘要

Objective: This study evaluated the glycosylated hemoglobin (HbA1c-lowering effect of colesevelam hydrochloride, a bile acid sequestrant, in subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy. Methods: After a 4-week placebo run-in period, subjects with type 2 diabetes and an HbA1c value of 7.0% to 10.0% were randomized to receive colesevelam 3.75 g/d or matching placebo for 12 weeks. Subjects' previous oral anti hyperglycemic medication (sulfonylurea and/or metformin) was continued throughout the study. Fasting blood samples were obtained at weeks −5, −1, 0, 1, 4, 8, and 12. The primary efficacy end point was the change in HbA1c from baseline to week 12. Secondary end points included changes in fructosamine levels, fasting plasma glucose levels, postprandial glucose level, and meal glucose response (ie, difference between preprandial and postprandial levels), and percent changes in lipid parameters from baseline to week 12. Results: The 65 randomized subjects (31 colesevelam, 34 placebo) had a mean age of 56.2 years and a mean body mass index of 32.4 kg/m2; 55.4% were male and 53.8% were white. The difference in least squares (LS) mean (SE) change in HbA1c between the colesevelam group and the placebo group was −0.5% (0.18) (P = 0.007). In subjects with a baseline HbAIc ≥ 8.0%, the difference in LS mean change in HbA1c was −1.0% (0.27) (P = 0.002). Relative to placebo, colesevelam treatment was associated with reductions in levels of fructosamine (−29.0 [10.9] pmol/L; P = 0.011) and postprandial glucose (−31.5 [13.6] mg/dL; P = 0.026). The mean percent change in low-density lipoprotein cholesterol was -9.6% in the colesevelam group, compared with 2.1% in the placebo group (treatment difference, −11.7% [4.2]; P = 0.007); the respective mean percent changes in total cholesterol were −4.0% and 3.4% (treatment difference, −7.3% [3.0]; P = 0.019). Colesevelam also was associated with significant decreases in the percent change in apolipoprotein B (P = 0.003) and low-density lipoprotein particle concentration (P = 0.037). The incidence of treatment-emergent adverse events (TEAEs) was similar in both groups, although treatment-related adverse events were more frequent in the colesevelam group than in the placebo group (29.0% vs 8.8%, respectively). The most frequent TEAEs in the colesevelam group were gastrointestinal disorders (22.6%), primarily constipation (19.4%), compared with an 8.8% incidence of gastrointestinal disorders (0% constipation) in the placebo group. There were no significant changes in body weight or the occurrence of hypoglycemia between treatment groups. Conclusions: In these subjects with type 2 diabetes, 12 weeks of colesevelam treatment were associated with significant reductions in HbA1c and in fructosamine and postprandial glucose levels compared with placebo. The 2 groups had a similar adverse-event profile, with the exception of an increased incidence of constipation in the colesevelam group. These results suggest that colesevelam may improve both lipid control and glycemic control in patients with type 2 diabetes receiving oral antihyperglycemic medications.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
共享精神的应助被凡凡采纳,获得10
1秒前
2秒前
万能图书馆的应助被小鞠佩奇采纳,获得10
3秒前
yyys完成签到,获得积分10
3秒前
Berta关注了科研通微信公众号
3秒前
烟花的应助被胡萝贝采纳,获得10
3秒前
李健的小迷弟的应助被FU采纳,获得10
3秒前
CC发布了新的文献求助10
4秒前
5秒前
周小鱼发布了新的文献求助10
5秒前
5秒前
顾矜的应助被陆羽采纳,获得10
6秒前
浅夏给浅夏的求助进行了留言
6秒前
共享精神的应助被h11采纳,获得10
7秒前
orixero的应助被小鱼采纳,获得10
7秒前
SciGPT的应助被samo采纳,获得10
7秒前
8秒前
9秒前
9秒前
10秒前
10秒前
DW的应助被yc采纳,获得10
10秒前
喜悦桥发布了新的文献求助10
10秒前
ZZM发布了新的文献求助10
10秒前
rainbow完成签到,获得积分10
10秒前
NexusExplorer的应助被hushan53采纳,获得10
10秒前
幸运星发布了新的文献求助10
10秒前
11秒前
宋博贤发布了新的文献求助10
12秒前
小鞠佩奇发布了新的文献求助10
13秒前
Ava的应助被阿飞大师采纳,获得10
14秒前
14秒前
初见完成签到,获得积分10
14秒前
hhhh发布了新的文献求助10
14秒前
小星星发布了新的文献求助10
15秒前
15秒前
15秒前
Alinse完成签到,获得积分10
16秒前
kkkkk完成签到 ,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163664
求助须知:如何正确求助?哪些是违规求助? 9557817
关于积分的说明 21741980
捐赠科研通 7754358
什么是DOI,文献DOI怎么找? 3428338
关于科研通互助平台的介绍 2553000
邀请新用户注册赠送积分活动 2472943